MEN1 and diabetes mellitus: Recent data showed that menin inhibitors (MI-463 and MI-503) epigenetically regulates the menin/JunD/Pbk axis, revealing a new (suppressive) mechanism of action useful to develop future drugs for treatment of diabetes, acting through the modulation of the beta cell mass and improvement of glucose control [89].